These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25305747)

  • 1. IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort.
    Markkula A; Simonsson M; Ingvar C; Rose C; Jernström H
    BMC Cancer; 2014 Oct; 14():759. PubMed ID: 25305747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.
    Markkula A; Simonsson M; Rosendahl AH; Gaber A; Ingvar C; Rose C; Jernström H
    Int J Cancer; 2014 Oct; 135(8):1898-910. PubMed ID: 24599585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Estrogen Receptor Alpha and Interleukin 6 Polymorphisms with Lymphovascular Invasion, Extranodal Extension, and Lower Disease-Free Survival in Thai Breast Cancer Patients.
    Sa-Nguanraksa D; Suntiparpluacha M; Kulprom A; Kummalue T; Chuangsuwanich T; Avirutnan P; O-Charoenrat P
    Asian Pac J Cancer Prev; 2016; 17(6):2935-40. PubMed ID: 27356714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients.
    Korobeinikova E; Myrzaliyeva D; Ugenskiene R; Raulinaityte D; Gedminaite J; Smigelskas K; Juozaityte E
    BMC Genet; 2015 Jun; 16():70. PubMed ID: 26112140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.
    Lei J; Rudolph A; Moysich KB; Rafiq S; Behrens S; Goode EL; Pharoah PP; Seibold P; Fasching PA; Andrulis IL; Kristensen VN; Couch FJ; Hamann U; Hooning MJ; Nevanlinna H; Eilber U; Bolla MK; Dennis J; Wang Q; Lindblom A; Mannermaa A; Lambrechts D; García-Closas M; Hall P; Chenevix-Trench G; Shah M; Luben R; Haeberle L; Ekici AB; Beckmann MW; Knight JA; Glendon G; Tchatchou S; Alnæs GI; Borresen-Dale AL; Nord S; Olson JE; Hallberg E; Vachon C; Torres D; Ulmer HU; Rüdiger T; Jager A; van Deurzen CH; Tilanus-Linthorst MM; Muranen TA; Aittomäki K; Blomqvist C; Margolin S; Kosma VM; Hartikainen JM; Kataja V; Hatse S; Wildiers H; Smeets A; Figueroa J; Chanock SJ; Lissowska J; Li J; Humphreys K; Phillips KA; ; Linn S; Cornelissen S; van den Broek SA; Kang D; Choi JY; Park SK; Yoo KY; Hsiung CN; Wu PE; Hou MF; Shen CY; Teo SH; Taib NA; Yip CH; Ho GF; Matsuo K; Ito H; Iwata H; Tajima K; Dunning AM; Benitez J; Czene K; Sucheston LE; Maishman T; Tapper WJ; Eccles D; Easton DF; Schmidt MK; Chang-Claude J
    Breast Cancer Res; 2015 Feb; 17(1):18. PubMed ID: 25849327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk.
    Slattery ML; Curtin K; Sweeney C; Wolff RK; Baumgartner RN; Baumgartner KB; Giuliano AR; Byers T
    Obesity (Silver Spring); 2008 Feb; 16(2):339-47. PubMed ID: 18239642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
    DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
    Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
    Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
    Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
    Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
    Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Infection-Induced Fever and the Interaction with IL6 rs1800796 Polymorphism on the Prognosis of Breast Cancer.
    Ye H; Tang LY; Liang ZZ; Chen QX; Li YQ; Liu Q; Xie X; Lin Y; Ren ZF
    Cancer Epidemiol Biomarkers Prev; 2022 Nov; 31(11):2030-2037. PubMed ID: 36084325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
    Sopik V; Sun P; Narod SA
    Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of angiogenesis and inflammation-related gene functional polymorphisms with early-stage breast cancer prognosis.
    Korobeinikova E; Ugenskiene R; Insodaite R; Rudzianskas V; Jaselske E; Poskiene L; Juozaityte E
    Oncol Lett; 2020 Jun; 19(6):3687-3700. PubMed ID: 32391092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of time to death after distant recurrence in breast cancer patients.
    Sopik V; Sun P; Narod SA
    Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
    Mulligan AM; Couch FJ; Barrowdale D; Domchek SM; Eccles D; Nevanlinna H; Ramus SJ; Robson M; Sherman M; Spurdle AB; Wappenschmidt B; Lee A; McGuffog L; Healey S; Sinilnikova OM; Janavicius R; Hansen Tv; Nielsen FC; Ejlertsen B; Osorio A; Muñoz-Repeto I; Durán M; Godino J; Pertesi M; Benítez J; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Cattaneo E; Bonanni B; Viel A; Pasini B; Papi L; Ottini L; Savarese A; Bernard L; Radice P; Hamann U; Verheus M; Meijers-Heijboer HE; Wijnen J; Gómez García EB; Nelen MR; Kets CM; Seynaeve C; Tilanus-Linthorst MM; van der Luijt RB; van Os T; Rookus M; Frost D; Jones JL; Evans DG; Lalloo F; Eeles R; Izatt L; Adlard J; Davidson R; Cook J; Donaldson A; Dorkins H; Gregory H; Eason J; Houghton C; Barwell J; Side LE; McCann E; Murray A; Peock S; Godwin AK; Schmutzler RK; Rhiem K; Engel C; Meindl A; Ruehl I; Arnold N; Niederacher D; Sutter C; Deissler H; Gadzicki D; Kast K; Preisler-Adams S; Varon-Mateeva R; Schoenbuchner I; Fiebig B; Heinritz W; Schäfer D; Gevensleben H; Caux-Moncoutier V; Fassy-Colcombet M; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Hardouin A; Berthet P; Muller D; Fricker JP; Mortemousque I; Pujol P; Coupier I; Lebrun M; Kientz C; Longy M; Sevenet N; Stoppa-Lyonnet D; Isaacs C; Caldes T; de la Hoya M; Heikkinen T; Aittomäki K; Blanco I; Lazaro C; Barkardottir RB; Soucy P; Dumont M; Simard J; Montagna M; Tognazzo S; D'Andrea E; Fox S; Yan M; Rebbeck T; Olopade O; Weitzel JN; Lynch HT; Ganz PA; Tomlinson GE; Wang X; Fredericksen Z; Pankratz VS; Lindor NM; Szabo C; Offit K; Sakr R; Gaudet M; Bhatia J; Kauff N; Singer CF; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Mai PL; Greene MH; Imyanitov E; O'Malley FP; Ozcelik H; Glendon G; Toland AE; Gerdes AM; Thomassen M; Kruse TA; Jensen UB; Skytte AB; Caligo MA; Soller M; Henriksson K; Wachenfeldt vA; Arver B; Stenmark-Askmalm M; Karlsson P; Ding YC; Neuhausen SL; Beattie M; Pharoah PD; Moysich KB; Nathanson KL; Karlan BY; Gross J; John EM; Daly MB; Buys SM; Southey MC; Hopper JL; Terry MB; Chung W; Miron AF; Goldgar D; Chenevix-Trench G; Easton DF; Andrulis IL; Antoniou AC; ; ; ; ; ; ; ;
    Breast Cancer Res; 2011; 13(6):R110. PubMed ID: 22053997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic and haplotype analysis of Interleukin-6 and -18 gene polymorphisms in association with clinicopathological factors in breast cancer.
    Padala C; Puranam K; Shyamala N; Kupsal K; Kummari R; Galimudi RK; Gundapaneni KK; Tupurani MA; Suryadevera A; Chinta SK; Manavathi B; Hanumanth SR
    Cytokine; 2022 Dec; 160():156024. PubMed ID: 36182709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States.
    Slattery ML; Curtin K; Baumgartner R; Sweeney C; Byers T; Giuliano AR; Baumgartner KB; Wolff RR
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):747-55. PubMed ID: 17416766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer.
    DeMichele A; Gray R; Horn M; Chen J; Aplenc R; Vaughan WP; Tallman MS
    Cancer Res; 2009 May; 69(10):4184-91. PubMed ID: 19435922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival.
    Boyapati SM; Shu XO; Ruan ZX; Cai Q; Smith JR; Wen W; Gao YT; Zheng W
    Clin Cancer Res; 2005 Feb; 11(3):1093-8. PubMed ID: 15709176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
    Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
    BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.